Related Experiment Video
Updated: Jul 5, 2026

Site-Specific Lysine Lactylation via Genetic Code Expansion in E. coli and Mammalian Cells
Published on: February 24, 2026
Radiation induces an EGFR-dependent lactate-epigenetic program underlying synergy with EGFR inhibition
Hongxia Cheng1, Lu Meng1, Shilan Luo1
1Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Purpose:
Clinical studies have suggested a therapeutic synergy between EGFR-TKIs and radiotherapy; however, the underlying mechanisms remain incompletely understood, particularly in tumors harboring the acquired resistance mutation EGFR T790M.
Methods:
Using EGFR T790M-positive cell lines, patient-derived organoids (PDOs), and patient-derived xenograft (PDX) models, we systematically investigated radiation responses in EGFR T790M-mutant tumors. Metabolic profiling, protein interaction and phosphorylation analyses, enzyme activity assays, chromatin immunoprecipitation sequencing (ChIP-seq), and DNA damage repair assessments were performed to elucidate the molecular mechanisms of therapeutic synergy between EGFR-TKIs and radiotherapy.
Results:
We show that EGFR T790M drives a radiation-amplified glycolytic program characterized by enhanced intracellular lactate accumulation. Radiation induces EGFR-dependent tyrosine phosphorylation and activation of lactate dehydrogenase A (LDHA), sustaining lactate production. Rather than being rapidly exported or oxidized, lactate is retained intracellularly and promotes histone H3 lysine lactylation (H3Kla) at promoter regions of DNA repair genes, establishing a repair-permissive chromatin state. This epigenetic priming enhances repair complex assembly, accelerates recruitment of repair factors to DNA double-strand breaks, and facilitates efficient DNA damage resolution. Genetic or pharmacological disruption of the LDHA-lactate axis impairs DNA repair and restores radiosensitivity. In EGFR T790M PDX models, targeting this metabolic pathway significantly enhances radiotherapy efficacy with acceptable toxicity.
Conclusions:
Our findings identify a previously unrecognized metabolic-epigenetic-repair axis through which EGFR T790M promotes radiotherapy resistance. This study redefines the functional role of EGFR T790M in radiation biology, provides mechanistic insight into the clinical synergy between EGFR inhibition and radiotherapy, and offers a rational framework for developing metabolism-informed combination radiotherapy strategies.
Insights
The EGFR T790M mutation amplifies glycolysis, leading to lactate buildup that shields tumors from radiation therapy by promoting DNA repair. Targeting this metabolic pathway restores radiosensitivity and improves treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Radiotherapy
Background:
- Clinical synergy between EGFR-TKIs and radiotherapy is observed.
- Mechanisms of this synergy are unclear, especially in EGFR T790M-mutant tumors.
Purpose of the Study:
- Investigate radiation responses in EGFR T790M-mutant tumors.
- Elucidate molecular mechanisms of therapeutic synergy between EGFR-TKIs and radiotherapy.
Main Methods:
- Utilized EGFR T790M-positive cell lines, organoids, and xenografts.
- Performed metabolic profiling, protein analyses, ChIP-seq, and DNA repair assessments.
Main Results:
- EGFR T790M drives radiation-amplified glycolysis and intracellular lactate accumulation.
- Lactate promotes histone lactylation, enhancing DNA repair gene expression and facilitating DNA damage resolution.
- Disrupting the LDHA-lactate axis restores radiosensitivity and improves radiotherapy efficacy in preclinical models.
Conclusions:
- Identified a metabolic-epigenetic-repair axis driving radiotherapy resistance in EGFR T790M tumors.
- Redefined the role of EGFR T790M in radiation biology.
- Provided a framework for metabolism-informed combination radiotherapy strategies.
Related Concept Videos
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Epigenetic Regulation
X-chromosome...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
